Endo International PLC (NASDAQ:ENDP)‘s stock had its “buy” rating reiterated by research analysts at Mizuho in a research report issued to clients and investors on Monday. They presently have a $29.00 target price on the stock. Mizuho’s target price would indicate a potential upside of 42.93% from the company’s current price.

Other equities research analysts have also recently issued research reports about the stock. Deutsche Bank AG reissued a “buy” rating and set a $31.00 price target on shares of Endo International PLC in a research report on Wednesday, June 15th. JMP Securities reaffirmed a “buy” rating on shares of Endo International PLC in a research report on Wednesday, June 29th. Vetr cut shares of Endo International PLC from a “strong-buy” rating to a “buy” rating and set a $19.14 target price for the company. in a research report on Thursday, July 7th. JPMorgan Chase & Co. set a $40.00 target price on shares of Endo International PLC and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Finally, Citigroup Inc. dropped their target price on shares of Endo International PLC from $40.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, September 16th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $39.32.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Shares of Endo International PLC (NASDAQ:ENDP) opened at 20.29 on Monday. The company’s market capitalization is $4.52 billion. Endo International PLC has a 12 month low of $12.56 and a 12 month high of $77.21. The firm has a 50-day moving average of $20.98 and a 200-day moving average of $22.03.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Monday, August 8th. The company reported $0.86 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.12. The business earned $921 million during the quarter, compared to analysts’ expectations of $873.50 million. Endo International PLC had a negative net margin of 25.90% and a positive return on equity of 15.54%. The firm’s revenue for the quarter was up 25.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.08 EPS. On average, equities analysts predict that Endo International PLC will post $4.56 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of ENDP. Norges Bank purchased a new position in shares of Endo International PLC during the fourth quarter valued at $97,137,000. Exxonmobil Investment Management Inc. TX increased its position in shares of Endo International PLC by 6.7% in the first quarter. Exxonmobil Investment Management Inc. TX now owns 49,773 shares of the company’s stock valued at $1,401,000 after buying an additional 3,115 shares in the last quarter. Aperio Group LLC increased its position in shares of Endo International PLC by 1.7% in the first quarter. Aperio Group LLC now owns 43,200 shares of the company’s stock valued at $1,216,000 after buying an additional 732 shares in the last quarter. Pacad Investment Ltd. purchased a new position in shares of Endo International PLC during the first quarter valued at $5,442,000. Finally, Massmutual Trust Co. FSB ADV increased its position in shares of Endo International PLC by 7.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 11,377 shares of the company’s stock valued at $320,000 after buying an additional 745 shares in the last quarter. 96.64% of the stock is currently owned by institutional investors and hedge funds.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

5 Day Chart for NASDAQ:ENDP

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.